None listed
Conditions
Interventions
T-SK group:Perioperative interactive intelligent follow-up with 0.3mg/kg ketamine intravenously administered 30 minutes before the end of the surgery
T-OP group:Perioperative interactive intelligent follow-up with intravenous opioid agonist (morphine 0.04mg/kg equivalent) 30 minutes before the end of the procedure
C-SK group:A traditional scheduled follow-up visit during the perioperative period was performed, and 0.3mg/kg esmolone was injected intravenously 30 minutes before the operation
C-OP group:Traditional scheduled follow-up during the perioperative period was performed with intravenous opioid agonist (0.04mg/kg equivalent dose of morphine) 30 minutes before the operation
Sponsors
The First Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >= 60 years, gender is not limited; 2. It is planned to undergo elective general anesthesia for digestive tract surgery, gynecological surgery, urological surgery, thoracic surgery, and orthopedic surgery; 3. ASA score II to IV; 4. Voluntarily accept postoperative patient-controlled intravenous analgesia diagnosis and treatment measures; 5. Sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Expected hospital stay < 72h; 2. Patients who are expected to be admitted to the ICU after surgery; 3. Those who are known to be allergic to opioid receptor agonists such as sufentanil citrate injection, fentanyl citrate injection, hydromorphone hydrochloride injection, morphine hydrochloride injectionand active ingredients or excipients of esketamine hydrochloride injection; 4. Patients with severe disturbance of consciousness or mental system diseases (schizophrenia, mania, bipolar disorder, mental disorder, etc.) and cognitive dysfunction; 5. Have a history of severe cardiovascular disease (congestive heart failure, severe angina pectoris, or unstable angina pectoris or myocardial infarction within 6 months); 6. Patients with MMSE score <18; 7. Patients with contraindications to the use of the trial drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of pulmonary complications (pulmonary infection, atelectasis, pleural effusion, pneumothorax, etc.) within 1 week after surgery;Incidence of delirium within 72 hours after surgery;Incidence of nausea and vomiting within 72 hours after surgery;Total postoperative opioids; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of anesthesia-related adverse events within 72 hours after surgery;Bedside FEV1 at 2h, 4h, 24h, 48h, and 72h post-surgery;Numerical scoring method pain scores at 2h, 4h, 24h, 48h, and 72h after surgery;Salvage analgesia rate within 72 hours after surgery;Postoperative recovery time of anal exhaust;Time to first stand up and get out of bed after operation;Pharmacoeconomic indicators;Analgesic efficacy score of patients with IPOQ 72h after surgery;Changes in postoperative cognitive function relative to baseline;Sleeping quality assessment; | — |
Countries
China
Contacts
Public ContactHuang Wenqi
The First Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed